Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
about
Glucagon-like peptide analogues for type 2 diabetes mellitusExendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's diseaseOne-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialAn Update on the Effect of Incretin-Based Therapies on β-Cell Function and MassRecent Progress in Anti-Obesity and Anti-Diabetes Effect of BerriesAssessment of pancreatic β-cell function: review of methods and clinical applicationsLiraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic miceβ-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)The evolving place of incretin-based therapies in type 2 diabetesDiabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapiesA physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairmentEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetesLiraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.The Anthocyanin Delphinidin 3-Rutinoside Stimulates Glucagon-Like Peptide-1 Secretion in Murine GLUTag Cell Line via the Ca2+/Calmodulin-Dependent Kinase II Pathway.Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice.Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor AgonistsGlucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese miceNeuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson's disease.Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPERLiraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and PharmacodynamicsTargeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.Potential of liraglutide in the treatment of patients with type 2 diabetes.Incretin-based therapies: viewpoints on the way to consensus.Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.Liraglutide in the management of type 2 diabetes.Add-on therapies to metformin for type 2 diabetes.The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.Liraglutide: clinical pharmacology and considerations for therapy.Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.Liraglutide: a review of its use in the management of type 2 diabetes mellitus.Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment.Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.
P2860
Q24235918-541019D2-36E8-428B-93C9-8C84F8B78946Q24647189-3DB5CEC7-8A60-4895-B46B-8725B34C4817Q24656644-2A75C8C9-050B-4001-AEB6-FEAB15F5DC4FQ26749089-DD9F3C4C-0DE4-41B9-8DBB-514B5661E180Q26750602-08FFB0A4-E85E-4224-9EF1-0B2648279261Q26829445-B7C128D6-9384-4200-A0FB-1B8128BA65FDQ28546996-9F648468-98F1-43ED-8098-F235AF0F1162Q33570085-6A501605-AD78-4BCC-80E6-748DD0439596Q33607749-690AB75B-352B-4734-A352-6FD5E824ECEAQ33608023-98BEFA13-7EB3-41C3-8865-E49FE55387DEQ33854032-D4ACF735-4C25-4453-BE66-3E0C4A8EDD99Q33866808-FDC09570-380F-4062-B856-BBA71E9FAFDFQ33949425-C2F4AFC7-CFAA-43B2-A7AA-4446823D4DBEQ34374321-9E9F5694-6C52-45F9-AD3F-13FABF32B1AFQ34407868-6979E7D0-70EA-4AE9-8249-C3C9DDE9E798Q34598940-830AF9A9-A464-432E-B955-72186864EAC1Q35179964-659EF4B7-9928-4905-BDD3-E50F592A5799Q35411439-00B43585-7FA0-4DE5-B40C-616B6CE64382Q35593684-31667E0F-FF99-40E6-89DA-1F3791C78C1FQ35801801-3AF486ED-1352-4F0D-8F65-D24A3D80EF92Q35936644-75F51E57-905F-42D0-ABDE-B43AB2F780CDQ36073461-0629FD4B-CAFE-42B3-ABD8-4F13476AF590Q36621486-AA091510-48D9-49BF-B61B-CC293931EF9DQ36737512-8ED3E5C1-D239-4092-BE9E-F05CB21B1CFAQ36800401-4E7F8E23-B96B-45C4-95C3-B7BC597A408EQ36924102-E3E0A1B9-70A5-418D-BE19-EF8F7A5C0471Q37270524-D7610CD3-18DF-4BDE-8B8B-1818FFFA6320Q37316259-4B73F0F2-5E43-4FC4-9D4C-4017FD6AA1BFQ37479037-4DCC7E03-ECB1-4AB0-B961-E476E3D4E4A1Q37624267-F29A6A08-F313-47E8-BF84-47B4799402E4Q37641329-531A40CA-BC54-4CB0-B90D-23AC18BE643BQ37813419-F4C9009E-BD07-4FF9-AB36-E8472E6672A7Q37818234-4BD4B0CB-3798-4818-B80D-1A99881172AFQ37864256-0F736535-97D7-4979-BCDC-CA92FEF5FE64Q37929159-1B5AC375-F7B8-4577-8664-988F97861897Q37933408-8CE0A75C-75C7-43A5-8688-8E3E30AE8E1FQ37940632-704F0343-E7E0-454B-AA25-4B02B1EEA66BQ37956408-EE44980C-C5FF-4351-BAC5-CFE24657E586Q37969039-3C72BF6B-9B76-4483-A556-922F9397FCBAQ38148574-F4E4922F-4CFB-4C1A-B714-55459F2255D5
P2860
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Liraglutide, a once-daily huma ...... with Type 2 diabetes mellitus.
@en
Liraglutide, a once-daily huma ...... with Type 2 diabetes mellitus.
@nl
type
label
Liraglutide, a once-daily huma ...... with Type 2 diabetes mellitus.
@en
Liraglutide, a once-daily huma ...... with Type 2 diabetes mellitus.
@nl
prefLabel
Liraglutide, a once-daily huma ...... with Type 2 diabetes mellitus.
@en
Liraglutide, a once-daily huma ...... with Type 2 diabetes mellitus.
@nl
P2093
P2860
P921
P1433
P1476
Liraglutide, a once-daily huma ...... with Type 2 diabetes mellitus.
@en
P2093
H-H Lervang
K Kølendorf
M Zdravkovic
T Vilsbøll
P2860
P304
P356
10.1111/J.1464-5491.2007.02333.X
P50
P577
2008-01-14T00:00:00Z